# Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Source: https://onco.cc/trials/nct05745623/  
OnCo record `nct05745623` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ICP-723 in brain and spinal cord tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.

## Summary

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors is a phase 1/2 interventional study registered as NCT05745623 by Beijing InnoCare Pharma Tech Co., Ltd., with 70 participants planned, started 2022-12-27 and due to reach its primary completion in 2027-12-25. Interventions recorded: ICP-723.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05745623
- Phase: 1/2
- Setting: A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05745623: https://clinicaltrials.gov/study/NCT05745623

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)

---
JSON: https://onco.cc/api/v1/entities/nct05745623.json